Third-generation Mineralocorticoid Receptor Antagonists: Why Do We Need a Fourth?

Area of Science:

• Pharmacology
• Endocrinology
• Molecular Biology

Background:

• Mineralocorticoid receptor (MR) antagonists, starting with spironolactone, were developed for primary aldosteronism and edema.
• Lack of selectivity and limited understanding of MR's diverse roles hindered development of newer generations.
• Despite decades of research, a third-generation MR antagonist is still unavailable.

Purpose of the Study:

• To review the development of MR antagonists.
• To highlight the challenges in creating third-generation MR antagonists.
• To propose future directions for MR antagonist and selective agonist development.

Main Methods:

• Literature review of MR antagonist development.
• Analysis of MR expression and function across different cell types.
• Discussion of molecular interactions and therapeutic targets.

Main Results:

• MR antagonists have evolved over decades, but selectivity remains a challenge.
• Inappropriate MR activation contributes to various pathological conditions.
• Understanding cell-type-specific MR actions is crucial for targeted therapies.

Conclusions:

• Future MR antagonists should selectively target inflammatory, fibrotic, and sympathetic nervous system effects.
• Development should avoid targeting renal tubular epithelium and specific neuronal populations.
• Fourth-generation antagonists and selective agonists require deeper insights into tissue and ligand-specific MR activation.